Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
This all seems positive to me, no change from what we already knew with no lag in anticipated timescales. As long as they can get the contracts with the various health care providers worldwide this should be a winner. This remains a share not ideally for widows and orphans but I’m happy to keep hold and fingers crossed my ship will come in.
Interesting article in Sunday Times magazine about robotic surgery. Creo are bang on the button for this and the normal laparoscopic techniques. The Da Vinci robots being described are made by Intuitive Surgical as referenced previously.
Placing of c. £31 million followed by open offer :-
The Company is pleased to announce that, further to the announcement made on 12 August 2021 (RNS No: 5145I ) regarding the Fundraising (the "Launch Announcement"), it is proposing to raise up to approximately £5.07 million (before expenses) through an Open Offer pursuant to which Qualifying Shareholders will have an opportunity to subscribe for an aggregate of 2,775,896 Open Offer Shares at an Offer Price of 182.5 pence per Open Offer Share.
From Creo Twitter
Following our EMEA and USA milestones, this week Speedboat UltraSlim was used for the first time in Latin America with Dr Michel Kahaleh, Dr Juan Alcivar and Dr Eduardo Albeniz performing #POEM & #FPOEM procedures at #IECED Hospital, Ecuador.
I am in full agreement. The thing clearly holding it back is any ongoing funding worry. If the sales go well however that concern should evaporate in a puff of contracts. I invested in these several years ago at much higher levels but came back in for a lot more recently having decided to take a chance on sales bringing in sufficient income to prevent any future dilutive fund raise. So fingers crossed.
A timely update on where this Company is and is going I could not be more pleased with the progress, it looks like this will go places.
Good to see some market confidence in this. As expressed they seem to be ready as a company to move on. Just a matter of getting the contracts now so fingers crossed
Nice to see an update dealing with my query. IMHO this is a nice slow burner with management pressing on on various fronts. We’ll done to Creo.
Anyone have any information as to how Creo are doing. I appreciate the price drift down is probably just lack of interest but if anyone thinks different I’d be interested to hear.
They’re looking to invest. It’s a new investment company.
Put simply Avacta has world beating technology on several fronts and the world now knows about it.
Furthermore on our Prime Minister the world (including Andy Burnham ) now knows it takes a very clever man to play the fool.
"For Bristol-Myers Squibb (BMY), the addition of Celgene gives it access to another blockbuster cancer drug, Revlimid. In 2018, Revlimid generated $9.67 billion in sales, accounting for 63% of Celgene revenue. Revlimid patents will soon expire, however."
Perhaps they could look to augment its efficacy by improving its precision and thus extending/renewing the patent?
Been in since before Covid - investing for the cancer treatments, obviously happy with the use of Affimers for Covid testing. Been reading all the posts with interest. By way of some background on Neil Bell the new executive Avacta have hired. You may be interested to know that Many years ago he helped to develop Copaxone, which was one of the biggest treatments for MS when it first came out! It’s been around since 1997 so there’s obviously better ones out there now but a small snippet to show the quality of people joining Can only bode well